Voriconazole pharmacokinetics and safety in immunocompromised children compared to adult patients. - Wikidata - awgldk - TriplyDB

Voriconazole pharmacokinetics and safety in immunocompromised children compared to adult patients.

Voriconazole pharmacokinetics and safety in immunocompromised children compared to adult patients.

http://www.wikidata.org/entity/Q34045383

about

Pharmacokinetics and pharmacodynamics of antifungals in children: clinical implications CYP2C19 polymorphisms and therapeutic drug monitoring of voriconazole: are we ready for clinical implementation of pharmacogenomics?Voriconazole plasma concentrations in immunocompromised pediatric patients vary by CYP2C19 diplotypes.Pharmacokinetics and safety of voriconazole intravenous-to-oral switch regimens in immunocompromised Japanese pediatric patients.Voriconazole monitoring in children with invasive fungal infections Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised children and healthy adults.Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised adolescents and healthy adults.Integrated population pharmacokinetic analysis of voriconazole in children, adolescents, and adults.Highly variable plasma concentrations of voriconazole in pediatric hematopoietic stem cell transplantation patients.Practice guidelines for therapeutic drug monitoring of voriconazole: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring.The use of antifungal therapy in neonatal intensive care.Voriconazole in clinical practice.Voriconazole serum concentrations in obese and overweight immunocompromised patients: a retrospective review.Pharmacokinetics and pharmacodynamics of antifungals in children and their clinical implications.Therapeutic drug monitoring in the treatment of invasive aspergillosis with voriconazole in cancer patients--an evidence-based approach.Pediatric Clinical Pharmacology of Voriconazole: Role of Pharmacokinetic/Pharmacodynamic Modeling in Pharmacotherapy.Pharmacokinetic considerations in treating invasive pediatric fungal infections.Pharmacodynamic studies of voriconazole: informing the clinical management of invasive fungal infections.An Optimized Voriconazole Dosing Strategy to Achieve Therapeutic Serum Concentrations in Children Younger than 2 Years Old.Efficacy of voriconazole in a murine model of acute Trypanosoma cruzi infection.Voriconazole dosing and therapeutic drug monitoring in children: experience from a paediatric tertiary care centre.Impact of the CYP2C19 genotype on voriconazole exposure in adults with invasive fungal infections.The Clinical Significance of Voriconazole Therapeutic Drug Monitoring in Children With Invasive Fungal Infections.Autoinduction of voriconazole metabolism in a child with invasive pulmonary aspergillosis.Aspergillosis in solid organ transplantation.Voriconazole induced bradycardia.Efficacy and safety of voriconazole in immunocompromised patients: systematic review and meta-analysis.

P2860

Q27025299-2423223E-B173-446A-B77B-9E5685E4692A Q33849298-B9224DD6-A11E-4DC7-91A0-15F77CB9BA78 Q34138276-807DE604-DCB0-4994-A5CA-B9810534073D Q35105949-B376FDDD-5D62-45E2-BC1E-D9CF40B3B3CA Q35157940-5E8DA4D2-EFB6-4783-848E-0CF142B0E5D4 Q35598464-D40A1E73-A35E-480D-ADBD-93016506D0B8 Q35598532-7AA209FF-5D04-4291-93B0-D0A82E79C03C Q36018595-FB136FCD-D8E2-4822-87E7-427490565F42 Q36505462-5509650A-BAF4-4E05-AAE6-167FF46B287F Q36927577-43507A0E-3C56-40B6-B66E-96E5BE0857EB Q37985070-09C65765-2DA2-447E-9785-F4497AB1B9C3 Q38061736-63ED39A5-810A-41BD-9FAA-2C24FE8ECB70 Q38073201-D55D3CA9-2259-43D1-AB4E-4A124577AB9A Q38193337-1CF44D8F-6180-420D-A11C-E896B266F7F1 Q38362057-9240D39F-AFA8-447F-8889-9E88E5EBC00C Q38775809-24967C0F-A348-4BFC-917D-A3A232630054 Q38816614-3EA5EA1D-8DC5-4F54-BFA9-C3866781BE60 Q38880522-351B6A2C-2463-49BD-BECF-F6EB6C2AE967 Q39466921-802DBF63-7708-4BF3-B7DA-E4653B13A077 Q39508383-81283CA9-7EBD-4785-A681-DB554FF77BCE Q39893350-20201791-7814-435F-830D-495E650F3B59 Q40290020-AC36149B-8E08-408C-8DCE-FAA2B84C3995 Q40913870-7E841C84-8FFC-4564-8EA9-3127D03182E2 Q41057395-3B0AFCED-9BC2-40F0-82D3-96E1DE707A1E Q42272291-6CF425C8-2C5F-47BF-B74A-BF01BC42424D Q45285590-063EA08D-A560-4ABE-9025-883148C92E3D Q47274881-F866BF49-1242-4956-9F0E-3B9C0B2B63D3

P2860

Voriconazole pharmacokinetics and safety in immunocompromised children compared to adult patients.

http://www.wikidata.org/entity/Q34045383

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Voriconazole pharmacokinetics ...... en compared to adult patients.

@ast

Voriconazole pharmacokinetics ...... en compared to adult patients.

@en

Voriconazole pharmacokinetics ...... en compared to adult patients.

@nl

type

label

Voriconazole pharmacokinetics ...... en compared to adult patients.

@ast

Voriconazole pharmacokinetics ...... en compared to adult patients.

@en

Voriconazole pharmacokinetics ...... en compared to adult patients.

@nl

prefLabel

Voriconazole pharmacokinetics ...... en compared to adult patients.

@ast

Voriconazole pharmacokinetics ...... en compared to adult patients.

@en

Voriconazole pharmacokinetics ...... en compared to adult patients.

@nl

P1433

Q34045383-63AAD36D-F3DB-49FA-98B5-09D599E272C8

P1476

Q34045383-80A63707-6269-4A82-80FC-D555C65AAED5

P2093

Q34045383-195CEA61-C991-41F3-BFF4-EE45D988B015

Q34045383-407D865A-A62B-491D-8D28-4FDCDDB623FA

Q34045383-485F15E1-65EB-4F53-99A8-BDDF5A075A60

Q34045383-50C658E1-C71C-455B-B6AA-EE1C63B993E9

Q34045383-55AB62F4-4F98-4BD4-AF12-CA3C371BA507

Q34045383-C2D85BEA-5173-4410-B481-6C2DB05C8340

Q34045383-D3D9A4A8-1ACD-41A4-BE5A-8541A8746068

Q34045383-DB8C354C-F886-4CE9-8E61-C788C5BCD8C8

P2860

Q34045383-035B0BF7-10D3-4B06-87AA-045DBC4EC7C4

Q34045383-04A83CEE-50CB-46AD-BD7D-B74A4D8686AF

Q34045383-0A6EF564-D16B-44B4-94A8-DAC68DEC2883

Q34045383-0B1E9108-C8CE-434D-8ABF-C983315E050D

Q34045383-163E75E7-5CB2-4109-8EB5-B3CF54F3F9A5

Q34045383-2FFDE0A6-FB97-46F7-9E3A-A573F5C6419E

Q34045383-37CEE9D9-D919-4D15-BEC7-4BD086AAD45D

Q34045383-3D56FEFA-6A50-48FF-AFA0-BD93A161833F

Q34045383-43C9E810-CBC4-4F39-B289-A73AA14AB049

Q34045383-476F06BD-782E-425B-B6A0-6A1B2811C662

P304

Q34045383-7A1B2847-85F2-46F1-A28A-98F4EA1D7DF0

P31

Q34045383-ACFEB310-41E8-4AF5-B2A9-9ECA306BFD60

P356

Q34045383-0A868FE3-099F-4DE5-AC8F-C9ABB4AA197E

P407

Q34045383-7CB34221-4DAF-449E-AB08-6C53AC7BD37D

P433

Q34045383-738BC31C-B486-46E9-8937-58FD414CB2DB

P478

Q34045383-500FD6D2-EEA8-4AA3-8096-E516612C96FD

P577

Q34045383-86D77D25-A28D-46C2-AA7F-708F2B76D85B

P698

Q34045383-AD9EB522-D282-4405-BA7C-7847E23311DF

P932

Q34045383-96F366BB-ECAC-4314-9A1A-086707225B4D

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Voriconazole pharmacokinetics ...... en compared to adult patients.

@en

P2093

Christine Mauz-Körholz

http://www.w3.org/2001/XMLSchema#string

Claudia Michael

http://www.w3.org/2001/XMLSchema#string

Dietger Niederwieser

http://www.w3.org/2001/XMLSchema#string

Katrin Frenzel

http://www.w3.org/2001/XMLSchema#string

Nadezda Basara

http://www.w3.org/2001/XMLSchema#string

Rainer Preiss

http://www.w3.org/2001/XMLSchema#string

Thoralf Lange

http://www.w3.org/2001/XMLSchema#string

Uta Bierbach

http://www.w3.org/2001/XMLSchema#string

P2860

Severe osteomyelitis caused by Myceliophthora thermophila after a pitchfork injury

Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America

In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens.

Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies.

Voriconazole pharmacokinetics and pharmacodynamics in children.

Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration.

In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: review of the literature.

Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus.

Efficacy of UK-109496, a new azole antifungal agent, in an experimental model of invasive aspergillosis.

Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety

P304

3225-3232

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.01731-09

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

54

http://www.w3.org/2001/XMLSchema#string

P577

2010-06-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20547816

http://www.w3.org/2001/XMLSchema#string

P932

2916341

http://www.w3.org/2001/XMLSchema#string